中外医学研究2025，Vol.23Issue(36)：153-155,3.DOI:10.14033/j.cnki.cfmr.2025.36.39
探讨维奈克拉联合阿扎胞苷治疗高危骨髓增生异常综合征的效果及安全性
Objective to Investigate the Effect and Safety of Venetoclax Combined with Azacitidine in the Treatment of High-Risk Myelodysplastic Syndrome
WANG Yinzhou 1QIU Lanyun 2QIU Luxi 2HUANG Xianglan 2LIAO Huiheng2
作者信息
- 1. Sanming Second Hospital,Sanming 366000,China
- 折叠
摘要
Abstract
Objective:To observe the effect and safety analysis of venetoclax combined with azacitidine in high-risk myelodysplastic syndrome(MDS).Method:A total of 60 cases of high-risk MDS admitted to the Sanming Second Hospital from January 2019 to January 2024 were selected as the research subjects and randomly divided into two groups by the random number table method,with 30 cases in each group.The control group was treated with azacitidine,while the study group was treated with venetoclax combined with azacitidine.The laboratory test indexes and evaluated effect were compared,and the adverse reactions were counted.Result:After the treatment,the white blood cell count,neutrophil and hemoglobin indexes were increased compared with those before treatment,and the study group was higher than that of the control group,while the indexes of β2-microglobulin,folate and lactate dehydrogenase were decreased compared with those before treatment,and the indexes of the study group were lower than those of the control group,with statistically significant differences(P<0.05).The total effective rate of the study group was higher than that of the control group,with a statistically significant difference(P<0.05).There was no significant difference in adverse drug reactions between the two groups(P>0.05).Conclusion:Venetoclax combined with azacitidine in the treatment of MDS can significantly improve the blood index level and improve the treatment effect with high safety.关键词
维奈克拉/阿扎胞苷/联合治疗/骨髓增生异常综合征/安全性Key words
Venetoclax/Azacitidine/Combination therapy/Myelodysplastic syndrome/Safety引用本文复制引用
WANG Yinzhou,QIU Lanyun,QIU Luxi,HUANG Xianglan,LIAO Huiheng..探讨维奈克拉联合阿扎胞苷治疗高危骨髓增生异常综合征的效果及安全性[J].中外医学研究,2025,23(36):153-155,3.
